Price (delayed)
$1.7
Market cap
$36.83M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.15
Enterprise value
$19.16M
Highlights
The EPS is down by 11% year-on-year but it is up by 4% since the previous quarter
Rein Therapeutics's net income has plunged by 126% YoY and by 16% from the previous quarter
RNTX's quick ratio has shrunk by 58% YoY and by 30% QoQ
Key stats
What are the main financial stats of RNTX
MarketValuationsEarnings
Shares outstanding
21.67M
Market cap
$36.83M
Enterprise value
$19.16M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.39
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$29.61M
Net income
-$29.24M
EBIT
-$29.24M
EBITDA
-$29.13M
Free cash flow
-$27.87M
Per shareBalance sheetLiquidity
EPS
-$3.15
EPS diluted
-$3.15
Free cash flow per share
-$1.29
Book value per share
$4.4
Revenue per share
$0
TBVPS
$0.86
Total assets
$104.22M
Total liabilities
$8.99M
Debt
$0
Equity
$95.23M
Working capital
$13.03M
Debt to equity
0
Current ratio
3.3
Quick ratio
3.12
Net debt/EBITDA
0.61
MarginsEfficiencyDividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-27.9%
Return on equity
-30.3%
Return on invested capital
N/A
Return on capital employed
-29.7%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RNTX stock price
How has the Rein Therapeutics stock price performed over time
Intraday
-2.3%
1 week
-3.95%
1 month
-10.53%
1 year
-70.89%
YTD
-26.09%
QTD
-3.95%
Financial performance
How have Rein Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$29.61M
Net income
-$29.24M
Gross margin
N/A
Net margin
N/A
RNTX financials
Rein Therapeutics's net income has plunged by 126% YoY and by 16% from the previous quarter
The operating income has dropped by 116% year-on-year and by 16% since the previous quarter
Growth
What is Rein Therapeutics's growth rate over time
RNTX growth chart
Valuation
What is Rein Therapeutics stock price valuation
P/E
N/A
P/B
0.39
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Price to earnings (P/E)
The EPS is down by 11% year-on-year but it is up by 4% since the previous quarter
Price to book (P/B)
RNTX's P/B is 70% below its 5-year quarterly average of 1.3 and 22% below its last 4 quarters average of 0.5
Rein Therapeutics's equity has decreased by 6% QoQ
Price to sales (P/S)
Efficiency
How efficient is Rein Therapeutics business performance
The ROE has soared by 67% YoY and by 9% from the previous quarter
The ROA has soared by 64% YoY and by 9% from the previous quarter
Dividends
What is RNTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RNTX.
Financial health
How did Rein Therapeutics financials performed over time
Assets vs liabilities
RNTX's current ratio has dropped by 58% year-on-year and by 30% since the previous quarter
RNTX's quick ratio has shrunk by 58% YoY and by 30% QoQ
Debt vs equity
The debt is 100% smaller than the equity
Rein Therapeutics's equity has decreased by 6% QoQ
Balance sheet
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from 
and Sharadar.